All In MedTech

Device Trial Radar · NCT05397106

Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Post-Market Clinical Follow-up of Patients With CODMAN CERTAS Plus Programmable Valve

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Actual

Start

Jan 24, 2023

Primary completion

Jan 24, 2029

Study completion Jan 24, 2029

Sponsor

Lead sponsor
Integra LifeSciences CorporationPublic (IART)
Sponsor type
Industry
First posted
May 31, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

Conditions

  • Hydrocephalus
  • Hydrocephalus in Children
  • NPH (Normal Pressure Hydrocephalus)
  • IIH - Idiopathic Intracranial Hypertension
  • Brain Tumor
  • Post-Traumatic Hydrocephalus
  • Hemorrhagic Stroke

Interventions

  • CODMAN CERTAS Plus Programmable ValveDevice

    Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Precise Device Placement: Maintaining Integrity and Functionality at 30 Days Post-DeploymentTime frame: 30 Days

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • University Hospital Leuven

    Leuven, Belgium

  • AZ Delta - Roeselare

    Roeselare, Belgium

  • Klinikum Dortmund Wirbelsäulenchirurgie

    Dortmund, Germany

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.